Canadian Securities Exchange Reports March 2022 Performance Figures

Canadian Securities Exchange Reports March 2022 Performance Figures

The Canadian Securities Exchange ("CSE" or "the Exchange") today announced its market statistics for the month of March 2022.

March 2022 Operating Statistics

  • Trading volume of CSE-listed securities totaled 2.0 billion shares;
  • Trading value of CSE-listed securities was $1.0 billion;
  • CSE issuers completed 71 financings that raised an aggregate $346 million; and
  • The CSE welcomed listings from 13 new companies, including two fundamental changes of existing issuers, bringing total listed securities to 770 as at March 31, 2022.

"The Canadian Securities Exchange was built largely on the back of the mining industry, so we are delighted by the recent strength in this sector," said Richard Carleton, CSE Chief Executive Officer. "During the month of March, mining companies on the CSE completed more financings and raised more capital than CSE-listed companies from any other sector. The activity was highlighted by Asante Gold Corp.'s $102.3 million financing, which represented the single largest financing completed by any of our mining issuers since 2016. With commodity prices booming and investor demand for mining securities remaining strong, our mining issuers are positioned for continued strength in the months ahead."

What's On at the CSE

With COVID-19 restrictions being eased across Canada, the CSE is excited to co-host the Capital Markets Comeback Tour! The tour, which is co-hosted by irlabs, features in-person investor events in Canada's four most populous cities: Vancouver (May 11), Calgary (May 12), Montreal (June 1), and Toronto (June 2). The events provide an opportunity to see interviews with top-tier public companies, speak with their senior management, and mingle with those peers in the investment community that you haven't seen outside of Zoom in two years. Registration and further details are available here.

The CSE is pleased to be a silver sponsor of the Benzinga Cannabis Capital Conference, a premier gathering of cannabis entrepreneurs and investors, to be held on April 20-21 in Miami, Florida. The in-person event features a wide range of interactive panels and presentations featuring the biggest names in the cannabis sector, one-on-one meeting booths, a new exclusive VIP lounge, and much more. Richard Carleton will speak on a panel on April 20 titled, "Companies Building Global Opportunities." Please click here for more information. Attendees are invited to stop by the CSE's booth and connect with members of the team.

The CSE is also pleased to be attending and co-sponsoring the Vancouver Resource Investment Conference, presented by Cambridge House International on May 17-18. The in-person conference features more than 225 commodity investment opportunities and a diverse line-up of high-profile speakers, including former Canadian Prime Minister Stephen Harper and former Mexican President Felipe Calderón. Please click here for more information and to register.

Richard Carleton will be speaking at the Scotiabank FinTech Conference, taking place at the bank's Toronto headquarters on May 17. Participants will hear from leaders in one of the world's most dynamic and rapidly-growing industries, and learn about exciting investment opportunities.

New Listings in March 2022

Albert Labs International Corp. (ABRT) - Fundamental Change
GeneTether Therapeutics Inc. (GTTX)
Gold Tree Resources Ltd. (GTX)
Voltage Metals Corp. (VOLT) - Fundamental Change
Nirvana Life Sciences Inc. (NIRV)
Cosa Resources Corp. (COSA)
Westmount Minerals Corp. (WMC)
Buscando Resources Corp. (BRCO)
Tactical Resources Corp. (RARE)
Gander Gold Corporation (GAND)
Recharge Resources Ltd. (RR)
Cannibble Food-Tech Ltd. (PLCN)
Labrador Uranium Inc. (LUR)

About the Canadian Securities Exchange:

The Canadian Securities Exchange is a rapidly growing stock exchange focused on working with entrepreneurs to access the public capital markets in Canada and internationally. The Exchange's efficient operating model, advanced technology and low fee structure help companies of all sizes minimize their cost of capital and maximize access to liquidity.

The CSE offers investors in Canada and abroad access to a multi-sector collection of growth companies through a liquid, reliable and highly regulated trading platform. The Exchange is dedicated to entrepreneurship and has established itself as a leading hub for discourse in the entrepreneurial community.

STAY CONNECTED WITH THE CSE
=============================
CSE TV on YouTube: https://www.youtube.com/csetv
#HashtagFinance Podcast: https://blog.thecse.com/pe-podcasts/
Instagram: https://www.instagram.com/canadianexchange/
Linkedin: https://ca.linkedin.com/company/canadian-securities-exchange
Facebook: https://www.facebook.com/CanadianSecuritiesExchange/
Twitter: https://twitter.com/CSE_News
Blog: https://blog.thecse.com/
Website: https://thecse.com/

Contact:
Richard Carleton, CEO
416-367-7360
richard.carleton@thecse.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/120783

News Provided by Newsfile via QuoteMedia

NIRV:CC
The Conversation (0)
Nirvana Life Sciences

Nirvana Life Sciences

Psychedelics for Opioid Addiction Recovery and Pain Management

Nirvana Life Sciences Inc. announces agreement to acquire the licensed distributor of a Patented, WHO approved, herbal treatment for opiate addiction

Nirvana Life Sciences Inc. announces agreement to acquire the licensed distributor of a Patented, WHO approved, herbal treatment for opiate addiction

Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV) a western Canadian based life sciences company aimed at developing psychedelic and other natural based medicines, including non-addictive chronic pain and relapse preventing pharmaceutical medicines, is pleased to report that it... Keep Reading...
Nirvana Life Sciences Inc. Announces the Appointment of Sheldon Inwentash to the Board of Directors

Nirvana Life Sciences Inc. Announces the Appointment of Sheldon Inwentash to the Board of Directors

Nirvana Life Sciences Inc.(CSE: NIRV) (Nirvana or the "Company") , a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce the appointment of Mr. Sheldon Inwentash to the Company's Board of Directors.Mr.... Keep Reading...
Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives

Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives

Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV) a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to report filing of a patent for D7-h. Nirvana... Keep Reading...
Nirvana Life Sciences Inc. Announces a Method for Producing MDMA that Reduces Manufacturing Time by Two Thirds

Nirvana Life Sciences Inc. Announces a Method for Producing MDMA that Reduces Manufacturing Time by Two Thirds

Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV) a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing pharmaceutical medicines and formulations to be used in trauma work,... Keep Reading...
Nirvana Life Sciences Inc. Announces License for a Delivery System for Psychedelic APIs

Nirvana Life Sciences Inc. Announces License for a Delivery System for Psychedelic APIs

Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV), a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to announce it has acquired an exclusive... Keep Reading...
Numinus Wellness Announces Change of Auditor

Numinus Wellness Announces Change of Auditor

Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that Davidson & Company LLP ("Davidson") has resigned as... Keep Reading...
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming... Keep Reading...
Dried mushrooms and capsules aligned on a light surface.

Psychedelics Market Update: H1 2025 in Review

The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America,... Keep Reading...
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various... Keep Reading...
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia.... Keep Reading...

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth... Keep Reading...

Latest Press Releases

Related News